 |
|
 |
 |
|
5
SEPTEMBER 2007
Innovative
Strategies for
Targeting EGFR
in NSCLC
A Breakfast Symposium
at the 12th IASLC
World Conference
on Lung Cancer
7:00
– 08:00
Seoul,
Korea
Coex Convention
Center
Chair:
Kaoru Kubota,
MD, PhD
National Cancer
Center
Hospital East
Kashiwa, Chiba,
Japan
Click
here to register
for this program
|
 |
|
F A C
U L T
Y |
 |
|
|
Walter
J.
Curran,
Jr.,
MD
Thomas
Jefferson
University
Philadelphia,
Pennsylvania,
United
States
|
Karen
Kelly,
MD
University
of
Kansas
Cancer
Center
Kansas
City,
Kansas,
United
States
|
Kaoru
Kubota,
MD
National
Cancer
Center
Hospital
East
Kashiwa,
Chiba,
Japan
|
|
|
|
S C I
E N T
I F I
C
A G E
N D A
|
|
|
|
6:45
Breakfast
Served
7:00
Welcome
Kaoru
Kubota,
MD
7:05
History
of
targeted
therapy
in
NSCLC
Kaoru
Kubota,
MD
7:20
Contemporary
strategies
for
targeting
EGFR
in
NSCLC
Karen
Kelly,
MD
7:40
The
emerging
role
of
EGFR
inhibitory
antibodies
in
combination
with
radiation
Walter
J.
Curran,
Jr.,
MD
7:50
Q&A/Panel
discussion
8:00
Adjourn
|
|
|
|
C O N
T I N
U I N
G M
E D I
C A L
E D U
C A T
I O N |
|
|
|
Imedex
Accreditation
Services,
LLC
is
accredited
by
the
Accreditation
Council
for
Continuing
Medical
Education
to
provide
continuing
medical
education
for
physicians.
Imedex
Accreditation
Services,
LLC
designates
this
educational
activity
for
a
maximum
1.00
AMA
PRA
Category
1
Credit(s)TM.
Physicians
should
only
claim
credit
commensurate
with
the
extent
of
their
participation
in
the
activity.
|
|
|
|
W H O
S H O
U L D
A T T
E N D
? |
|
|
|
This
educational
activity
is
intended
for
oncologists,
radiation
therapists,
thoracic
surgeons,
pulmonologists
and
other
physicians
in
active
clinical
practice
interested
and/or
involved
in
the
management
of
patients
with
non-small
cell
lung
cancer.
No
specialized
knowledge
or
skills
other
than
a
general
familiarity
with
cancer
and
its
treatment
is
required
for
successful
participation
in
this
activity.
|
|
|
|
O B J
E C T
I V E
S |
|
|
|
After
successfully
completing
this
continuing
medical
education
activity
participants
should
be
able
to:
- Discuss
the
historical
use
of
targeted
agents
in
the
management
of
non-small
cell
lung
cancer
(NSCLC),
including
the
rationale
for
targeting
EGFR.
-
Evaluate
clinical
evidence
for
the
use
of
monoclonal
antibodies
designed
to
inhibit
EGFR
in
the
management
of
NSCLC.
- Assess
the
potential
role
of
radiotherapy
in
combination
with
EGFR
inhibitory
antibodies
for
the
treatment
of
NSCLC.
|
|
|
|
|
R E G
I S T
R A T
I O N |
|
|
|
Click
here
to
register
for
this
program
This
is
a complimentary educational activity for all IASLC attendees.
Please
pre-register in order to confirm your attendance.
You
may
register
online
or
call
Imedex
at
+1
(678)
242
0906
Registration
confirmations
will
be
issued
before
the
meeting.
|
|
|
|
O R G
A N I
Z E R |
|
|
|
|
|
©
2007 Imedex Accreditation
Services LLC.
All rights reserved.
Reproduction in
whole or part
is prohibited
without prior
written consent
from Imedex and
contributing faculty.
|
